Author:
De Schutter Tim,Andrei Graciela,Topalis Dimitri,Duraffour Sophie,Mitera Tania,van den Oord Joost,Matthys Patrick,Snoeck Robert
Abstract
Abstract
Background
Insights into the mechanisms associated with chemotherapy-resistance are important for implementation of therapeutic strategies and for unraveling the mode of action of chemotherapeutics. Although cidofovir (CDV) has proven efficacious in the treatment of human papillomavirus (HPV)-induced proliferation, no studies concerning the development of resistance to CDV in HPV-positive tumor cells have been performed yet.
Methods
From the cervical carcinoma SiHa cells (SiHa
parental
), which are HPV-16 positive, cidofovir-resistant cells (SiHa
CDV
) were selected, and differential gene expression profiles were analyzed by means of microarrays. We examined in vitro phenotyping of resistant cells compared to parental cells as well as tumorigenicity and pathogenicity in a mouse-xenograft model.
Results
SiHa
CDV
had a resistant phenotype and a reduced growth both in vitro and in vivo. A markedly diminished inflammatory response (as measured by production of host- and tumor-derived cytokines and number of neutrophils and macrophages in spleen) was induced by SiHa
CDV
than by SiHa
parental
in the xenograft model. Gene expression profiling identified several genes with differential expression upon acquisition of CDV-resistance and pointed to a diminished induction of inflammatory response in SiHa
CDV
compared to SiHa
parental
.
Conclusions
Our results indicate that acquisition of resistance to cidofovir in SiHa cells is linked to reduced pathogenicity. The present study contributes to our understanding on the antiproliferative effects of CDV and on the mechanisms involved, the inflammatory response playing a central role.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Reference71 articles.
1. De Clercq E: Acyclic nucleoside phosphonates: past, present and future Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol. 2006, 73: 911-922.
2. De Clercq E: The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 2007, 75: 1-13. 10.1016/j.antiviral.2006.10.006
3. Andrei G, Fiten P, Goubau P, van Landuyt H, Gordts B, Selleslag D: Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl Infect Dis. 2007, 9: 126-131. 10.1111/j.1399-3062.2006.00186.x
4. Kuypers DR: Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol. 2012, 8: 390-402. 10.1038/nrneph.2012.64
5. Snoeck R, De Clercq E: Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs. 2002, 3: 1561-1566.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献